Browse by author
Lookup NU author(s): Professor Alan Calvert
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Safety and efficacy trials comparing carboplatin and cisplatin, especially in ovarian cancer, have shown that the two drugs have a similar efficacy profile. Carboplatin, however, is significantly less toxic than cisplatin. The total costs of carboplatin and cisplatin therapy, which include not only drug costs but all health care costs incurred in preventing and managing toxicity, therefore differ considerably. Thus, despite carboplatin's considerably more expensive cost per dose, when the total costs of treatment are considered, carboplatin treatment is certainly no more expensive, and in many countries may be less expensive, than cisplatin therapy.
Author(s): Calvert AH, Urie J
Publication type: Article
Publication status: Published
Journal: Seminars in Oncology
Year: 1991
Volume: 18
Issue: 1 Supplement 2
Pages: 28-31
Print publication date: 01/02/1991
ISSN (print): 0093-7754
ISSN (electronic): 1532-8708
PubMed id: 1992533
